Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years. Remunity ® Pump for Remodulin ® (treprostinil; ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...

RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an ...

Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age. The Food and Drug Administration (FDA) has granted ...

Patients with pulmonary arterial hypertension will shortly have a more convenient way to treat their disease. United Therapeutics and DEKA Research & Development have received the Food and Drug ...

United Therapeutics specializes in therapies for pulmonary arterial hypertension (PAH), or high blood pressure in the lungs. Its marketed PAH portfolio includes prostacyclin analogs Remodulin ...

United reported a mixed fourth quarter, with some inventory adjustments negatively impacting revenue for its treprostinil products (Remodulin, Tyvaso, and Orenitram) in pulmonary hypertension, or PH.

RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an ...

RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., May 7, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of 510(k) ...